Policy + commercial momentum for Alzheimer’s/PD/DLB blood/CSF/gut biomarkers + treatments [climaxing]
Key Questions
What are the key results from Anavex Life Sciences' blarcamesine trial?
Anavex's blarcamesine showed 37-69% brain volume preservation over 3 years via MRI and cognitive data, with a 77-week delay in NDA push. The company is presenting at the 25th Annual Needham Virtual Healthcare Conference.
What is the status of CervoMed's neflamapimod for Lewy Body Dementia?
CervoMed's neflamapimod demonstrated MRI atrophy slowdown in DLB Ph2b, with Ph3 planned for H2'26. They will provide a clinical program update and participate in a biomarkers panel at the 2026 Lewy Body Dementia Association Annual Meeting.
What are the costs of Parkinson's disease in the US for 2024?
A new report shows Parkinson's costs surpassed $82 billion in the US in 2024, highlighting the growing financial burden on patients and caregivers. The NIH has invested $600M in a PD pipeline with over 100 therapies.
How has IGC Pharma progressed in their CALMA trial for Alzheimer's agitation?
IGC Pharma's CALMA Ph2 trial for agitation in Alzheimer's is 70% enrolled, with Tandem Clinical Research added to the trial sites. This targets a significant unmet need in dementia care.
What preliminary results did NeuroTherapia's NTRX-07 show in Phase 2a?
NeuroTherapia completed Phase 2a of NTRX-07, a novel treatment for Alzheimer's, reporting it was safe with preliminary trends in reducing neuroinflammation.
How does APOE4 affect the brain before memory loss in Alzheimer's?
APOE4 disrupts the brain pre-symptomatically, causing reversible hyperactivity via Nell2, as per recent studies. Research from Miller School highlights APOE4/ABCA7 interactions at AD/PD conferences.
What accuracy do p-tau217/181 blood biomarkers have for Alzheimer's?
p-tau217/181 blood biomarkers achieve 90% accuracy for Alzheimer's detection. Initiatives like Grey Matters/Catalyst are rolling out PET imaging, and VAI is advancing blood biomarkers.
Are there sex differences in Alzheimer's screening tools?
A Georgia State University study shows standard cognitive screening tools for Alzheimer's may work differently for women and men. This underscores the need for sex-specific screening approaches.
Anavex blarcamesine 3yr MRI/cog data 37-69% brain vol preserve, 77wk delay NDA push; Alzheon ALZ-507 oral anti-amyloid APOE4 Ph1; NeuroTherapia NTRX-07 Ph2a safe prelim trends neuroinflam; IGC CALMA Ph2 70% enrolled agitation; CervoMed neflamapimod DLB Ph2b MRI atrophy slowdown Ph3 H2'26; AD sex-diff screening; APOE4 Nell2 pre-symptom reversible hyperactivity; repurposing ZINC000019796155; PD NIH $600M/pipeline 100+ thx, $82B US 2024 costs; Miller APOE4/ABCA7; VAI blood biom; p-tau217/181 90%; Grey Matters/Catalyst PET rollout; TPP; Kisunla RWE; CAR-T/TREM2/PCSK9/SleepFM/gut-metabs; TrialMatch AI 1000+ users; Alz Assoc Springfield event.